Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00704847 |
|
Recruitment Status :
Terminated
(Male subjects were terminated due to an imbalance in prostate cancer events)
First Posted : June 25, 2008
Results First Posted : September 12, 2012
Last Update Posted : April 24, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Osteoarthritis | Drug: Oral Salmon Calcitonin Drug: Oral Salmon Calcitonin (Placebo) | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1030 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis |
| Study Start Date : | June 2008 |
| Actual Primary Completion Date : | May 2011 |
| Actual Study Completion Date : | June 2011 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 1
SMC021 Oral Calcitonin
|
Drug: Oral Salmon Calcitonin
0.8mg SMC021, twice daily |
|
Placebo Comparator: 2
SMC021 Placebo
|
Drug: Oral Salmon Calcitonin (Placebo)
0.8mg Placebo, twice daily |
- Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months [ Time Frame: Change from baseline to 24 months ]The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.
- Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index [ Time Frame: Change from baseline to 24 months ]WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).
- Bone & Cartilage Metabolism Biochemical Marker Change (Percentage). [ Time Frame: From baseline to 24 months ]The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24.
- Knee Disease Progression Assessed by MRI [ Time Frame: From baseline to month 12 and month 24 ]Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.
- Questionnaire to Assess Function and Physical Activity [ Time Frame: From baseline to months 1, 6, 12 and 24 ]
Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992):
I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities.
III. Able to perform usual self-care activities, but limited in vocational and avocational activities.
IV. Limited ability to perform usual self-care activities, vocational and avocational activities.
Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific.
- Questionnaire to Assess Stiffness in the Signal Knee. [ Time Frame: Baseline to month 24 ]
WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness).
Patients were instructed not to take analgesics for 3 days prior to the WOMAC test.
- Questionnaire to Assess Health-related Quality of Life [ Time Frame: From baseline to month 24 ]
Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years.
The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state).
The change from baseline in the EQ-5D VAS was calculated.
- Questionnaire to Assess Pain [ Time Frame: Baseline, month 1, month 6, month 12, month 24 ]Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled "No Pain" and 100 equaled "Worst Pain Imaginable". Patients were instructed not to take analgesics for 3 days prior to the VAS.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 51 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Medical history and symptoms of knee osteoarthritis
Exclusion Criteria:
- Any other disease or medication affecting the bone or cartilage.
- Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial.
Other protocol defined inclusion/exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704847
Show 18 study locations
| Study Director: | Bente Juel Riis, MD | Nordic Bioscience |
| Responsible Party: | Nordic Bioscience A/S |
| ClinicalTrials.gov Identifier: | NCT00704847 |
| Other Study ID Numbers: |
CSMC021C2302 |
| First Posted: | June 25, 2008 Key Record Dates |
| Results First Posted: | September 12, 2012 |
| Last Update Posted: | April 24, 2019 |
| Last Verified: | April 2019 |
|
Osteoarthritis, oral salmon calcitonin, treatment, efficacy, tolerability |
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Calcitonin |
Salmon calcitonin Calcitonin Gene-Related Peptide Katacalcin Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Bone Density Conservation Agents Vasodilator Agents |